Obstructive sleep apnea (OSA) is one of the most common — and most underdiagnosed — chronic conditions in adults. The American Academy of Sleep Medicine estimates roughly 30 million U.S. adults have OSA, yet fewer than a quarter have a formal diagnosis. For decades, the answer has been a continuous positive airway pressure (CPAP) machine. Now, new pharmacologic and device-based options are changing the conversation.
What Sleep Apnea Actually Does to the Body
In obstructive sleep apnea, the throat muscles relax during sleep and repeatedly block the airway, causing dozens of brief breathing pauses each hour. Each interruption triggers a stress response: oxygen levels dip, the heart rate spikes, and the brain partially rouses to restore breathing.
The long-term consequences are not subtle. Research published in the Journal of the American College of Cardiology links untreated moderate-to-severe OSA with elevated risk of hypertension, atrial fibrillation, heart failure, and stroke. A 2023 analysis in The Lancet Respiratory Medicine reported that adults with severe OSA had roughly a 2.5-fold higher risk of cardiovascular mortality compared with unaffected peers. Studies also indicate associations with type 2 diabetes, daytime cognitive impairment, and accelerated brain aging on MRI imaging.
Why CPAP Is Still the First-Line Therapy
CPAP remains the most studied and most effective treatment for moderate-to-severe OSA. By delivering a steady stream of pressurized air through a mask, the device keeps the airway open throughout the night. When used consistently, CPAP can normalize the apnea-hypopnea index (AHI), reduce daytime sleepiness, and lower blood pressure.
The catch is adherence. Research suggests roughly 30–50% of patients struggle to use CPAP consistently for the four-plus hours per night considered effective. Mask discomfort, claustrophobia, dry airways, and partner disruption are commonly cited reasons. That gap between efficacy and real-world use has driven a search for alternatives.
Tirzepatide: A Pharmacologic Breakthrough
In December 2024, the U.S. Food and Drug Administration approved tirzepatide (brand name Zepbound) for the treatment of moderate-to-severe OSA in adults with obesity — the first medication ever cleared specifically for sleep apnea. The decision was based on the SURMOUNT-OSA trials, published in The New England Journal of Medicine in June 2024.
In the two phase 3 studies, adults with obesity and moderate-to-severe OSA received either tirzepatide or placebo for 52 weeks. Participants on tirzepatide saw their AHI drop by an average of 25–29 events per hour — roughly two-thirds — compared with much smaller reductions in placebo groups. Many participants no longer met criteria for moderate or severe OSA at trial end. Body weight, blood pressure, and inflammatory markers also improved.
The mechanism is largely indirect. Excess weight, especially around the neck and upper airway, is the single strongest modifiable driver of OSA. By reducing weight, tirzepatide eases mechanical airway compression. Researchers caution that the drug is not a substitute for CPAP in all patients, particularly those with non-obesity-related OSA or severe oxygen desaturation, but it expands the toolkit substantially for the largest patient subgroup.
Oral Appliances for Mild-to-Moderate Cases
For people with milder OSA or those who cannot tolerate CPAP, custom-fitted mandibular advancement devices have a growing evidence base. These dental appliances reposition the lower jaw slightly forward during sleep, enlarging the airway. A 2022 meta-analysis in Sleep Medicine Reviews found that oral appliances reduce AHI by about 50% on average — less than CPAP but with notably higher adherence rates.
Effectiveness varies by anatomy, and appliances should be fitted by a dentist trained in sleep medicine. Side effects can include jaw discomfort and bite changes over time.
Hypoglossal Nerve Stimulation
An implantable device that gently stimulates the hypoglossal nerve — which controls tongue movement — has emerged as an option for select patients with moderate-to-severe OSA who cannot use CPAP. The device (commercially known as Inspire) senses each breath and contracts the tongue muscles to keep the airway open.
The pivotal STAR trial, with five-year follow-up data published in Otolaryngology–Head and Neck Surgery, showed sustained reductions in AHI and significant improvements in daytime sleepiness. The therapy requires outpatient surgery and is generally reserved for patients within specific anatomic and body-mass-index criteria.
Surgery, Positional Therapy, and Lifestyle
For a minority of patients, upper-airway surgery — including tonsillectomy, soft-palate procedures, or maxillomandibular advancement — remains a consideration, especially when a clear anatomic obstruction is identified.
Positional therapy can help individuals whose OSA worsens significantly when sleeping on the back. Wearable devices and specialized pillows that discourage supine sleep have modest but measurable effects.
Lifestyle measures still play a foundational role, regardless of which medical therapy is used:
- Weight management. Even a 10% reduction in body weight can meaningfully lower AHI in many patients.
- Alcohol and sedatives. Both relax airway muscles and can worsen apnea episodes, particularly in the hours before sleep.
- Smoking cessation. Smoking is associated with increased upper-airway inflammation and worse OSA severity.
- Side sleeping. A simple positional change reduces airway collapse for many patients.
- Nasal congestion management. Treating allergies or structural nasal issues can improve breathing during sleep.
When to Seek Evaluation
Common signs that warrant a conversation with a healthcare provider include loud habitual snoring, witnessed breathing pauses, choking or gasping during sleep, excessive daytime sleepiness, morning headaches, and unexplained nighttime awakenings. Risk increases with age, male sex, obesity, large neck circumference, and family history.
At-home sleep apnea tests have made diagnosis more accessible than ever. For straightforward cases, a single overnight recording with a portable device can quantify AHI and oxygen desaturation. More complex presentations may still require an in-lab polysomnogram.
The Bigger Picture
The treatment landscape for sleep apnea has shifted from a single-option model to a layered approach combining medical therapy, devices, behavioral change, and surgery in tailored combinations. Research on tirzepatide is likely just the beginning — trials of other GLP-1 and dual-agonist medications in OSA are ongoing.
For the millions living with undiagnosed or untreated sleep apnea, the practical takeaway is that there are now more pathways than ever to restful, restorative sleep. The earlier the conversation begins, the more options remain available to protect long-term cardiovascular and cognitive health.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.